Cedar Falls Health Care Center | |
1728 West Eighth Street, Cedar Falls, Iowa 50613 | |
(319) 277-2437 | |
Name | Cedar Falls Health Care Center |
---|---|
Location | 1728 West Eighth Street, Cedar Falls, Iowa |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 82 |
Occupancy Rate | 51.34% |
Medicare ID (CCN) | 165197 |
Legal Business Name | Premier Estates 511 Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1093171795 |
Organization Name | PREMIER ESTATES 511, LLC |
Doing Business As | CEDAR FALLS HEALTH CARE CENTER |
Address | 1728 W 8th St, Cedar Falls, IA 50613 |
Phone Number | 319-277-2437 |
News Archive
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
Researchers of the Cancer Metabolism group at the Bellvitge Biomedical Research Institute (IDIBELL), Catalan Oncology Institute (ICO) and the Division of Hematology-Oncology of the University of Cincinnati, led by George Thomas, have discovered a role for ribosomal 5S RNA in the formation of a complex that regulates the stability of p53.
Exciting headlines about the cancer-preventing potential of berries, red wine, and other foods are in the news almost every day. An article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine, highlights the researchers trying to make medicines based on substances in those foods and turn their potential into reality.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Entrepreneurs working to improve the lives and promote the independence of patients may soon benefit from an initiative run by the Massachusetts Medical Device Development Center.
› Verified 6 days ago
NPI Number | 1306837125 |
Organization Name | WAVERLEY - CEDAR FALLS HEALTH CARE CENTER, INC. |
Doing Business As | CEDAR FALLS HEALTH CARE CENTER |
Address | 1728 W 8th St, Cedar Falls, IA 50613 |
Phone Number | 319-277-2437 |
News Archive
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
Researchers of the Cancer Metabolism group at the Bellvitge Biomedical Research Institute (IDIBELL), Catalan Oncology Institute (ICO) and the Division of Hematology-Oncology of the University of Cincinnati, led by George Thomas, have discovered a role for ribosomal 5S RNA in the formation of a complex that regulates the stability of p53.
Exciting headlines about the cancer-preventing potential of berries, red wine, and other foods are in the news almost every day. An article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine, highlights the researchers trying to make medicines based on substances in those foods and turn their potential into reality.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Entrepreneurs working to improve the lives and promote the independence of patients may soon benefit from an initiative run by the Massachusetts Medical Device Development Center.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
Researchers of the Cancer Metabolism group at the Bellvitge Biomedical Research Institute (IDIBELL), Catalan Oncology Institute (ICO) and the Division of Hematology-Oncology of the University of Cincinnati, led by George Thomas, have discovered a role for ribosomal 5S RNA in the formation of a complex that regulates the stability of p53.
Exciting headlines about the cancer-preventing potential of berries, red wine, and other foods are in the news almost every day. An article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine, highlights the researchers trying to make medicines based on substances in those foods and turn their potential into reality.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Entrepreneurs working to improve the lives and promote the independence of patients may soon benefit from an initiative run by the Massachusetts Medical Device Development Center.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $17069 |
Number of Payment Denials | 0 |
Total Number of Penalties | 2 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 15.68 | 14.46 |
Percentage of long-stay residents who lose too much weight | 7.73 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 18.8 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.09 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.92 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 91.18 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 23.87 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 70.31 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 13.45 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.19 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 7.77 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.24 | 95.98 |